Effectiveness of inactivated COVID-19 vaccine against the severity of Omicron variant
Hao Wang, Li Liu, Tangchun Wu()
Ministry of Education and State Key Laboratory of Environmental Health (Incubating), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
. [J]. Frontiers of Medicine, 2023, 17(3): 576-580.
Hao Wang, Li Liu, Tangchun Wu. Effectiveness of inactivated COVID-19 vaccine against the severity of Omicron variant. Front. Med., 2023, 17(3): 576-580.
A Pan, L Liu, C Wang, H Guo, X Hao, Q Wang, J Huang, N He, H Yu, X Lin, S Wei, T Wu. Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China. JAMA 2020; 323(19): 1915–1923 https://doi.org/10.1001/jama.2020.6130
pmid: 32275295
2
One World in Data. Coronavirus (COVID-19) Vaccinations, England. 2022
3
OJ Watson, G Barnsley, J Toor, AB Hogan, P Winskill, AC Ghani. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis 2022; 22(9): 1293–1302 https://doi.org/10.1016/S1473-3099(22)00320-6
pmid: 35753318
4
SY Tartof, JM Slezak, L Puzniak, V Hong, TB Frankland, BK Ackerson, H Takhar, OA Ogun, S Simmons, JM Zamparo, L Jodar, JM McLaughlin. BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5. Lancet Infect Dis 2022; 22(12): 1663–1665 https://doi.org/10.1016/S1473-3099(22)00692-2
pmid: 36306800
5
N Andrews, J Stowe, F Kirsebom, S Toffa, T Rickeard, E Gallagher, C Gower, M Kall, N Groves, AM O’Connell, D Simons, PB Blomquist, A Zaidi, S Nash, Binti Abdul Aziz N Iwani, S Thelwall, G Dabrera, R Myers, G Amirthalingam, S Gharbia, JC Barrett, R Elson, SN Ladhani, N Ferguson, M Zambon, CNJ Campbell, K Brown, S Hopkins, M Chand, M Ramsay, Bernal J Lopez. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med 2022; 386(16): 1532–1546 https://doi.org/10.1056/NEJMoa2119451
pmid: 35249272
6
Z Huang, S Xu, J Liu, L Wu, J Qiu, N Wang, J Ren, Z Li, X Guo, F Tao, J Chen, D Lu, X Sun, W Wang. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. BMC Med 2022; 20(1): 400 https://doi.org/10.1186/s12916-022-02606-8
pmid: 36266697
7
DY Lin, Y Gu, Y Xu, B Wheeler, H Young, SK Sunny, Z Moore, D Zeng. Association of primary and booster vaccination and prior infection with SARS-CoV-2 infection and severe COVID-19 outcomes. JAMA 2022; 328(14): 1415–1426 https://doi.org/10.1001/jama.2022.17876
pmid: 36155617
Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: who to vaccinate first? Sci Adv 2021; 7(6): eabf1374 doi:10.1126/sciadv.abf1374
pmid: 33536223
10
SB Omer, PN Malani. Booster vaccination to prevent COVID-19 in the era of Omicron: an effective part of a layered public health approach. JAMA 2022; 327(7): 628–629 https://doi.org/10.1001/jama.2022.0892
pmid: 35061011
11
World Health Organization. COVID-19 vaccination roll-out stagnates in Africa. 2022
12
Central People’s Government of the People’s Republic of China. The press conference for the control and prevention of COVID-19 Epidemic, China. 2021
13
FC Zhu, XH Guan, YH Li, JY Huang, T Jiang, LH Hou, JX Li, BF Yang, L Wang, WJ Wang, SP Wu, Z Wang, XH Wu, JJ Xu, Z Zhang, SY Jia, BS Wang, Y Hu, JJ Liu, J Zhang, XA Qian, Q Li, HX Pan, HD Jiang, P Deng, JB Gou, XW Wang, XH Wang, W Chen. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020; 396(10249): 479–488 https://doi.org/10.1016/S0140-6736(20)31605-6
pmid: 32702299
14
Z FuD LiangW ZhangD ShiY MaD WeiJ XiS YangX XuD TianZ ZhuM GuoL JiangS YuS WangF JiangY LingS WangS ChenF LiuY TanX Fan. Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai. Front Med 2023; [Epub ahead of print] doi: https://doi.org/10.1007/s11684-022-0977-3
pmid: 36949347
15
Y Gao, T Li, M Han, X Li, D Wu, Y Xu, Y Zhu, Y Liu, X Wang, L Wang. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 2020; 92(7): 791–796 https://doi.org/10.1002/jmv.25770
pmid: 32181911
16
JJ Zhang, YY Cao, G Tan, X Dong, BC Wang, J Lin, YQ Yan, GH Liu, M Akdis, CA Akdis, YD Gao. Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. Allergy 2021; 76(2): 533–550 https://doi.org/10.1111/all.14496
pmid: 32662525
17
C Zheng, W Shao, X Chen, B Zhang, G Wang, W Zhang. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis 2022; 114: 252–260 https://doi.org/10.1016/j.ijid.2021.11.009
pmid: 34800687
18
P Nordström, M Ballin, A Nordström. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet 2022; 399(10327): 814–823 https://doi.org/10.1016/S0140-6736(22)00089-7
pmid: 35131043
L Kompaniyets, AF Pennington, AB Goodman, HG Rosenblum, B Belay, JY Ko, JR Chevinsky, LZ Schieber, AD Summers, AM Lavery, LE Preston, ML Danielson, Z Cui, G Namulanda, H Yusuf, WR Mac Kenzie, KK Wong, J Baggs, TK Boehmer, AV Gundlapalli. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020–March 2021. Prev Chronic Dis 2021; 18: 210123 https://doi.org/10.5888/pcd18.210123
pmid: 34197283
21
World Health Organization. COVID-19 vaccines technical documents. 2021
22
A Utami, A Margawati, D Pramono, A Nugraheni, SG Pramudo. Determinant factors of COVID-19 vaccine hesitancy among adult and elderly population in Central Java, Indonesia. Patient Prefer Adherence 2022; 16: 1559–1570 https://doi.org/10.2147/PPA.S365663
pmid: 35789823
R Tsai, J Hervey, K Hoffman, J Wood, J Johnson, D Deighton, D Clermont, B Loew, SL Goldberg. COVID-19 vaccine hesitancy and acceptance among individuals with cancer, autoimmune diseases, or other serious comorbid conditions: cross-sectional, internet-based survey. JMIR Public Health Surveill 2022; 8(1): e29872 https://doi.org/10.2196/29872
pmid: 34709184
25
H Chung, S He, S Nasreen, ME Sundaram, SA Buchan, SE Wilson, B Chen, A Calzavara, DB Fell, PC Austin, K Wilson, KL Schwartz, KA Brown, JB Gubbay, NE Basta, SM Mahmud, CH Righolt, LW Svenson, SE MacDonald, NZ Janjua, M Tadrous, JC; Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators Kwong. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ 2021; 374: n1943 https://doi.org/10.1136/bmj.n1943
pmid: 34417165
26
A Paternina-Caicedo, M Jit, N Alvis-Guzmán, JC Fernández, J Hernández, JJ Paz-Wilches, J Rojas-Suarez, C Dueñas-Castell, NJ Alvis-Zakzuk, AD Smith, F Hoz-Restrepo. Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study. Lancet Reg Health Am 2022; 12: 100296 https://doi.org/10.1016/j.lana.2022.100296
pmid: 35791428
27
G Lu, Y Zhang, H Zhang, J Ai, L He, X Yuan, S Bao, X Chen, H Wang, J Cai, S Wang, W Zhang, J Xu. Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave. Emerg Microbes Infect 2022; 11(1): 2045–2054 https://doi.org/10.1080/22221751.2022.2109517
pmid: 35924388
28
L Coppeta, O Balbi, Z Grattagliano, GG Mina, A Pietroiusti, A Magrini, M Bolcato, M Trabucco Aurilio. First dose of the BNT162b2 mRNA COVID-19 vaccine reduces symptom duration and viral clearance in healthcare workers. Vaccines (Basel) 2021; 9(6): 659 https://doi.org/10.3390/vaccines9060659
pmid: 34204252
29
Hopkins University COVID-19 Resource Center Johns. COVID-19 dashboard by the center for systems science and engineering at Johns Hopkins University, the USA. 2022
30
JRC Pulliam, C van Schalkwyk, N Govender, A von Gottberg, C Cohen, MJ Groome, J Dushoff, K Mlisana, H Moultrie. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science 2022; 376(6593): eabn4947 https://doi.org/10.1126/science.abn4947
pmid: 35289632
31
E Eythorsson, HL Runolfsdottir, RF Ingvarsson, MI Sigurdsson, R Palsson. Rate of SARS-CoV-2 reinfection during an omicron wave in Iceland. JAMA Netw Open 2022; 5(8): e2225320 https://doi.org/10.1001/jamanetworkopen.2022.25320
pmid: 35921113
32
AA Mensah, J Lacy, J Stowe, G Seghezzo, R Sachdeva, R Simmons, A Bukasa, S O’Boyle, N Andrews, M Ramsay, H Campbell, K Brown. Disease severity during SARS-CoV-2 reinfection: a nationwide study. J Infect 2022; 84(4): 542–550 https://doi.org/10.1016/j.jinf.2022.01.012
pmid: 35085659
33
S Medić, C Anastassopoulou, Z Lozanov-Crvenković, V Vuković, N Dragnić, V Petrović, M Ristić, T Pustahija, Z Gojković, A Tsakris, JPA Ioannidis. Risk and severity of SARS-CoV-2 reinfections during 2020–2022 in Vojvodina, Serbia: a population-level observational study. Lancet Reg Health Eur 2022; 20: 100453 https://doi.org/10.1016/j.lanepe.2022.100453
pmid: 35791336
34
H WangY YuanB WuM XiaoZ WangT DiaoR ZengL ChenY LeiP LongY GuoX LaiY WenW LiH CaiL SongW NiY ZhaoK OuyangJ WangQ WangL LiuC WangA PanX LiR GongT Wu. Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents. Front Med 2023; [Epub ahead of print] doi: https://doi.org/10.1007/s11684-022-0954-x
pmid: 36738428
35
JM Carreño, H Alshammary, J Tcheou, G Singh, AJ Raskin, H Kawabata, LA Sominsky, JJ Clark, DC Adelsberg, DA Bielak, AS Gonzalez-Reiche, N Dambrauskas, V; PSP-PARIS Study Group; Srivastava K Vigdorovich, DN Sather, EM Sordillo, G Bajic, Bakel H van, V Simon, F Krammer. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 2022; 602(7898): 682–688 https://doi.org/10.1038/s41586-022-04399-5
pmid: 35016197
